Literature DB >> 28570348

Early infectious outcomes after addition of fluoroquinolone or aminoglycoside to posttrauma antibiotic prophylaxis in combat-related open fracture injuries.

Bradley A Lloyd1, Clinton K Murray, Faraz Shaikh, M Leigh Carson, Dana M Blyth, Elizabeth R Schnaubelt, Timothy J Whitman, David R Tribble.   

Abstract

BACKGROUND: We examined combat-related open extremity fracture infections as a function of whether posttrauma antimicrobial prophylaxis included expanded Gram-negative (EGN) coverage.
METHODS: Military personnel with open extremity fractures sustained in Iraq and Afghanistan (2009-2014) who transferred to participating hospitals in the United States were assessed. The analysis was restricted to patients with a U.S. hospitalization period of ≥7 days. Prophylaxis was classified as narrow (e.g., IV cefazolin, clindamycin, and/or amoxicillin-clavulanate) or EGN, if the prophylactic regimen included fluoroquinolones and/or aminoglycosides.
RESULTS: The study population included 1,044 patients, of which 585 (56%) and 459 (44%) received narrow and EGN coverage, respectively (p < 0.001). Skin and soft-tissue infections (SSTIs) were more common among patients who received narrow prophylaxis compared to EGN coverage (28% vs. 22%; p = 0.029), whereas osteomyelitis rates were comparable between regimens (8%). Similar findings were noted when endpoints were measured at 2 and 4 weeks postinjury. There was no significant difference related to length of hospitalization between narrow and EGN regimens (median: 34 and 32 days, respectively) or operating room visits (median: 5 and 4). A higher proportion of EGN coverage patients had Gram-negative organisms isolated that were not susceptible to fluoroquinolones and/or aminoglycosides (49% vs. 40%; p < 0.001). In a Cox proportional model, narrow prophylaxis was independently associated with an increased risk of extremity SSTIs (hazard ratio: 1.41; 95% confidence interval: 1.09-1.83). DISCUSSION: Despite seeing a small benefit with EGN coverage related to a reduction of SSTIs, it does not decrease the risk of osteomyelitis, and there seems to be a cost of increased antibiotic resistance associated with use. Overall, our findings support the current post-combat trauma antibiotic prophylaxis guidelines, which recommend the use of cefazolin or clindamycin with open fractures. LEVEL OF EVIDENCE: Prognostic/Epidemiological, Level II; Therapy, level IV.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28570348      PMCID: PMC5656510          DOI: 10.1097/TA.0000000000001609

Source DB:  PubMed          Journal:  J Trauma Acute Care Surg        ISSN: 2163-0755            Impact factor:   3.313


  23 in total

1.  Practice management guidelines for prophylactic antibiotic use in penetrating abdominal trauma: the EAST Practice Management Guidelines Work Group.

Authors:  F A Luchette; A P Borzotta; M A Croce; P A O'Neill; D H Whittmann; C D Mullins; F Palumbo; M D Pasquale
Journal:  J Trauma       Date:  2000-03

Review 2.  Surgical Infection Society guideline: prophylactic antibiotic use in open fractures: an evidence-based guideline.

Authors:  Carl J Hauser; Charles A Adams; Soumitra R Eachempati
Journal:  Surg Infect (Larchmt)       Date:  2006-08       Impact factor: 2.150

Review 3.  Prevention of infections associated with combat-related extremity injuries.

Authors:  Clinton K Murray; William T Obremskey; Joseph R Hsu; Romney C Andersen; Jason H Calhoun; Jon C Clasper; Timothy J Whitman; Thomas K Curry; Mark E Fleming; Joseph C Wenke; James R Ficke
Journal:  J Trauma       Date:  2011-08

4.  Efficacy of point-of-injury combat antimicrobials.

Authors:  Clinton K Murray; Duane R Hospenthal; Russ S Kotwal; Frank K Butler
Journal:  J Trauma       Date:  2011-08

Review 5.  The injury severity score--importance and uses.

Authors:  S Linn
Journal:  Ann Epidemiol       Date:  1995-11       Impact factor: 3.797

Review 6.  Guidelines for the prevention of infections associated with combat-related injuries: 2011 update: endorsed by the Infectious Diseases Society of America and the Surgical Infection Society.

Authors:  Duane R Hospenthal; Clinton K Murray; Romney C Andersen; R Bryan Bell; Jason H Calhoun; Leopoldo C Cancio; John M Cho; Kevin K Chung; Jon C Clasper; Marcus H Colyer; Nicholas G Conger; George P Costanzo; Helen K Crouch; Thomas K Curry; Laurie C D'Avignon; Warren C Dorlac; James R Dunne; Brian J Eastridge; James R Ficke; Mark E Fleming; Michael A Forgione; Andrew D Green; Robert G Hale; David K Hayes; John B Holcomb; Joseph R Hsu; Kent E Kester; Gregory J Martin; Leon E Moores; William T Obremskey; Kyle Petersen; Evan M Renz; Jeffrey R Saffle; Joseph S Solomkin; Deena E Sutter; David R Tribble; Joseph C Wenke; Timothy J Whitman; Andrew R Wiesen; Glenn W Wortmann
Journal:  J Trauma       Date:  2011-08

7.  East Practice Management Guidelines Work Group: update to practice management guidelines for prophylactic antibiotic use in open fractures.

Authors:  William S Hoff; John A Bonadies; Riad Cachecho; Warren C Dorlac
Journal:  J Trauma       Date:  2011-03

8.  Impact of Body Mass Index and Bacterial Resistance in Osteomyelitis after Antibiotic Prophylaxis of Open Lower-Extremity Fractures.

Authors:  Derek Bremmer; Brandon Bookstaver; Mark Cairns; Kenneth Lindley; Martin Durkin; David Koon; April Miller Quidley
Journal:  Surg Infect (Larchmt)       Date:  2017-02-27       Impact factor: 2.150

9.  Adherence to published antimicrobial prophylaxis guidelines for wounded service members in the ongoing conflicts in Southwest Asia.

Authors:  Bradley A Lloyd; Amy C Weintrob; Mary K Hinkle; Gerald R Fortuna; Clinton K Murray; William Bradley; Eugene V Millar; Faraz Shaikh; Kristen Vanderzant; Stacie Gregg; Gina Lloyd; Julie Stevens; M Leigh Carson; Deepak Aggarwal; David R Tribble
Journal:  Mil Med       Date:  2014-03       Impact factor: 1.437

Review 10.  Antibiotics for preventing infection in open limb fractures.

Authors:  R A Gosselin; I Roberts; W J Gillespie
Journal:  Cochrane Database Syst Rev       Date:  2004
View more
  8 in total

1.  Antibiotic Practice Patterns for Extremity Wound Infections among Blast-Injured Subjects.

Authors:  Laveta Stewart; Ping Li; Maj Dana M Blyth; Wesley R Campbell; Joseph L Petfield; Margot Krauss; Lauren Greenberg; David R Tribble
Journal:  Mil Med       Date:  2020-01-07       Impact factor: 1.437

2.  After the Battlefield: Infectious Complications among Wounded Warriors in the Trauma Infectious Disease Outcomes Study.

Authors:  David R Tribble; Clinton K Murray; Bradley A Lloyd; Anuradha Ganesan; Katrin Mende; Dana M Blyth; Joseph L Petfield; Jay McDonald
Journal:  Mil Med       Date:  2019-11-01       Impact factor: 1.437

3.  Evaluation of infection rates with narrow versus broad-spectrum antibiotic regimens in civilian gunshot open-fracture injury.

Authors:  Jordan A Woolum; Abby M Bailey; Adam Dugan; Rahul Agrawal; Regan A Baum
Journal:  Am J Emerg Med       Date:  2019-07-23       Impact factor: 2.469

4.  Antimicrobial Prophylaxis with Combat-Related Open Soft-Tissue Injuries.

Authors:  Bradley A Lloyd; Clinton K Murray; Faraz Shaikh; M Leigh Carson; Dana M Blyth; Elizabeth R Schnaubelt; Timothy J Whitman; David R Tribble
Journal:  Mil Med       Date:  2018-09-01       Impact factor: 1.437

Review 5.  IDCRP Combat-Related Extremity Wound Infection Research.

Authors:  Joseph L Petfield; Louis R Lewandowski; Laveta Stewart; Clinton K Murray; David R Tribble
Journal:  Mil Med       Date:  2022-05-04       Impact factor: 1.563

6.  IDCRP Trauma-Related Infection Research.

Authors:  David R Tribble
Journal:  Mil Med       Date:  2022-05-04       Impact factor: 1.563

Review 7.  Department of Defense Trauma Registry Infectious Disease Module Impact on Clinical Practice.

Authors:  David R Tribble; Mary Ann Spott; Stacey A Shackleford; Jennifer M Gurney; Bg Clinton K Murray
Journal:  Mil Med       Date:  2022-05-04       Impact factor: 1.563

8.  Infection prevention for open fractures: Is antibiotic monotherapy equivalent to multitherapy?

Authors:  Andrew C Miller; Stanislaw P Stawicki
Journal:  Int J Crit Illn Inj Sci       Date:  2019-09-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.